https://www.selleckchem.com/products/cp-91149.html
929). #link# Week 8 HAMD-17 scores and MCP-1 levels were significantly negatively correlated in treatment non-responders to CBX or PBO (P=0.05. Non-responders had significantly lower MCP-1 levels vs. responders at weeks 4 (P=0.049) and 8 (P=0.014). MCP-1 was positively correlated with pro-inflammatory analytes in the PBO group and with anti-inflammatory analytes in the CBX group. Combination treatment reduced treatment resistance and augmented antidepressant response. Baseline plasma MCP-1 levels were not altered in BDD patients. Sin
Like
Comment
Share
